# PharmaBlock CMC Lifecycle Strategy Forum: Smarter Decisions Across the Drug Development Lifecycle

- Link: https://www.thailand-business-news.com/pr-news/pharmablock-cmc-lifecycle-strategy-forum-smarter-decisions-across-the-drug-development-lifecycle
- Published: 2026-11-09T15:29:00+07:00
- Author: PR Newswire

_Lifecycle-based CMC strategies can help biotech companies balance speed, risk and
long-term asset value as programs advance globally_

NANJING, China, Nov. 9, 2026 /PRNewswire/ — PharmaBlock hosted its CMC Lifecycle
Strategy Forum in Nanjing on November 5 and 6, bringing together experienced pharmaceutical
development leaders and technical experts to explore how smarter, stage-appropriate
CMC decisions can improve development efficiency and program readiness.

 [⌊Panelists at the PharmaBlock CMC Lifecycle Strategy Forum⌉](https://mmx.prnasia.com/media/MS2030344/20261109011512EST_image_1.jpg?id=OA3065756&p=medium600)

Panelists at the PharmaBlock CMC Lifecycle Strategy Forum

As China-based biotech companies accelerate global development through out-licensing
and international partnerships, prospective partners are looking beyond scientific
differentiation and clinical potential. Developability, process and quality readiness,
clinical supply, and commercial preparedness are becoming increasingly important
in determining whether a promising program can progress reliably through clinical
development, partnership, and commercialization.

The forum brought together experts with senior R&D experience at AstraZeneca, AbbVie,
Bayer, and Pfizer, alongside professionals from Seda Pharmaceutical, Jacobio Pharma,
Benemae, and PharmaBlock. Discussions covered candidate developability, chemical
and drug product development, solid-state science, model-informed drug development,
clinical supply, phase-appropriate CMC strategies, and commercial manufacturing.

**"The value of CMC is not measured by the volume of work performed, but by how 
effectively that work helps a program move forward."**

"A development partner needs to understand where a program stands, what the next
milestone requires, and how the right expertise and evidence can be brought together
to support progress," said Yaohui Ji, Senior Vice President and Head of CDMO Business
at PharmaBlock.

**Stage-appropriate development, not simply more development**

A recurring theme throughout the forum was that earlier CMC involvement should not
mean moving every late-stage activity to the front of a program. Instead, teams 
should identify the questions and risks that are critical to the current development
stage while maintaining a clear view of future clinical, regulatory, and commercial
requirements.

In early development, priorities may include candidate developability, API properties,
solid form, formulation performance, drug exposure, and fit-for-purpose clinical
supply. As programs advance, the focus progressively shifts toward deeper process
and product understanding, analytical and control strategies, technology transfer,
validation, batch consistency, and reliable commercial supply.

Speakers also examined how chemical route and process decisions can affect development
timelines, scale-up, manufacturing economics, and future supply. Discussions on 
model-informed drug development demonstrated how API properties, formulation performance,
pharmacokinetics, and exposure-response relationships can be connected to support
dose selection and product development decisions.

**Connecting expertise across the development lifecycle**

A panel discussion translated these principles into practical development and partnership
scenarios, including candidate selection, formulation, drug exposure, process optimization,
clinical supply, due diligence, and partnership readiness.

Ahead of the forum, participants visited the PharmaBlock Research Institute and 
PharmaBlock OPC R&D Center in Nanjing. The visits highlighted PharmaBlock’s work
in continuous flow chemistry, high-throughput experimentation, and process analytical
technologies, as well as development capabilities for oligonucleotides, peptides,
and conjugates.

As an integrated CRDMO partner supporting programs from early discovery through 
commercial manufacturing, PharmaBlock brings together expertise across discovery
chemistry, process development, solid-state science, drug product development, analytical
development, and manufacturing.

Through the CMC Lifecycle Strategy Forum, PharmaBlock aims to connect global drug
development experience with China’s innovation ecosystem and help biotech companies
generate the right evidence at the right time as programs advance toward clinical
milestones, global partnerships, and commercialization.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [PharmaBlock CMC Lifecycle Strategy Forum: Smarter Decisions Across the Drug Development Lifecycle ](https://www.prnasia.com/story/archive/5092344_CN92344_0?rand=184833)